DLBCL is an aggressive disease2
Remarkably, more than half of patients are able to survive diffuse large B-cell
lymphoma (DLBCL) for 5 years or longer.1,3
Although strides have been made in the science of DLBCL,
we’re casting an even wider net to further our knowledge of this
aggressive disease
To learn more, visit BCellResearch.com
References: 1. Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2012. National
Cancer Institute website. http://seer.cancer.gov/csr/1975_2012/results_single/sect_19_table.29_2pgs.pdf. Updated
April 23, 2015. Accessed June 15, 2015. 2. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH.
Introduction and overview of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL,
et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International
Agency for Research on Cancer; 2008:158-166. 3. Larouche J-F, Berger F, Chassagne-Clément C, et al. Lymphoma
recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol.
2010;28(12):2094-2100.